Pharmaceuticals North America

North America Psychedelic Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

North America Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.84 Bn Placeholder estimate
Estimate 2025 $2.06 Bn 53.8% of the global market
Projected 2034 $5.81 Bn 181.8% Adds $3.75 Bn over 9 forecast years
CAGR 2025–2034 12.2% Faster than 71% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • North America is 53.8% of the global market.
  • Among regions, the largest is North America (this report) at $2.06 Bn.
  • Fastest growing: APAC at 14.4% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.75 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Psychedelic Therapeutics Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.84 Bn — —
2025 (base) $2.06 Bn +$224.1 Mn —
2026 (forecast) $2.31 Bn +$251.4 Mn +12.2%
2027 (forecast) $2.59 Bn +$282.1 Mn +25.9%
2028 (forecast) $2.91 Bn +$316.5 Mn +41.2%
2029 (forecast) $3.27 Bn +$355.2 Mn +58.5%
2030 (forecast) $3.66 Bn +$398.5 Mn +77.8%
2031 (forecast) $4.11 Bn +$447.1 Mn +99.5%
2032 (forecast) $4.61 Bn +$501.7 Mn +123.8%
2033 (forecast) $5.18 Bn +$562.9 Mn +151.2%
2034 (forecast) $5.81 Bn +$631.5 Mn +181.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.83 Bn
  2. North America (this report) $2.06 Bn
  3. US $1.55 Bn
  4. APAC $765.0 Mn
  5. Europe $709.6 Mn
  6. China $325.4 Mn
  7. Canada $276.7 Mn
  8. Japan $237.6 Mn
  9. Latin America $163.3 Mn
  10. Middle East $151.4 Mn
  11. Germany $120.6 Mn
  12. UK $109.5 Mn
  13. France $108.8 Mn
  14. Italy $101.7 Mn
  15. Brazil $88.9 Mn
  16. Ecuador $78.0 Mn
  17. India $80.7 Mn
  18. Saudi Arabia $71.7 Mn
  19. Spain $67.7 Mn
  20. Mexico $65.2 Mn
  21. Africa $66.4 Mn
  22. Australia $45.3 Mn
  23. New Zealand $42.8 Mn
  24. Russia $33.5 Mn
  25. South Africa $24.5 Mn
  26. UAE $18.5 Mn
  27. Egypt $9.8 Mn
  28. Philippines $8.0 Mn
  29. Hong Kong $6.3 Mn
  30. Malaysia $5.4 Mn
  31. Thailand $5.3 Mn
  32. Singapore $5.0 Mn
  33. Kenya $2.5 Mn

Report snapshot

North America Psychedelic Therapeutics Market Analysis at a glance
Market size, 2025$2.06 Bn placeholder estimate
Forecast, 2034$5.81 Bn placeholder estimate
Growth (CAGR), 2025–203412.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsCompound, indication and end user (see all)
Key playersCompass Pathways, Lykos Therapeutics, MindMed, Cybin, atai Life Sciences (see all)
Active clinical trials134 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Psychedelic Therapeutics Market Analysis Executive Summary

Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.

Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).

Bar chart: North America Psychedelic Therapeutics market size, 2024–2034, placeholder estimates. $1.84 Bn in 2024, $2.06 Bn in 2025 and $5.81 Bn in 2034, 12.2% CAGR.
North America Psychedelic Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Psychedelic Therapeutics Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.

Competitive Landscape for Psychedelic Therapeutics Market in North America

The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Psychedelic Therapeutics Market in North America

Psychedelic Therapeutics in North America: rules, payment and research

In the countries we cover here, medicines are approved by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4]. ClinicalTrials.gov lists 134 studies on Psychedelic Therapeutics that are recruiting, active or about to start in North America.⁠[5]

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[5] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Psychedelic Therapeutics right now, from free public sources.

Clinical trials

134 active trials in US and Canada

Recruiting, about to start, or running now. Counted across the 2 countries we report on in North America.

Top trial sponsors (worldwide)

  1. Compass Pathways 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 30 papers since 2021 (worldwide)

  1. Evolutionary neuropharmacology of serotonergic psychedelics: a cross-species perspective on mechanisms, consciousness, and therapeutic potential. Molecular psychiatry, 2026
  2. Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms. ACS medicinal chemistry letters, 2026
  3. The Timing of Plasticity: Beyond Synapses in Psychedelic Therapeutics. Biological psychiatry, 2026
  4. Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics. Frontiers in neuroscience, 2026
  5. Thalamic 5-HT(2A) receptor activation reduces GABA uptake, increases tonic GABA(A) inhibition and induces absence seizures in Wistar rats. Neuropharmacology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Psychedelic Therapeutics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Psychedelic Therapeutics market in North America?
Placeholder estimate: about $2.06 Bn in 2025, rising to about $5.81 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Psychedelic Therapeutics market in North America growing?
Placeholder estimate: about 12.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Psychedelic Therapeutics market report cover?
The report splits the market by compound (Psilocybin, MDMA, LSD, DMT and 5-MeO-DMT and more), indication (Treatment-Resistant Depression, PTSD, Substance Use Disorder, Anxiety) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Psychedelic Therapeutics market?
Key players include Compass Pathways, Lykos Therapeutics, MindMed, Cybin and atai Life Sciences.
What is driving the Psychedelic Therapeutics market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.
How many clinical trials on Psychedelic Therapeutics are running in North America?
134 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on Psychedelic Therapeutics?
PubMed lists 30 papers on Psychedelic Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Psychedelic Therapeutics in North America? Our analysts can size it for your plan. Talk to us See the public data Suicide rate for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in North America

See all
Same topic, other categories

Related on mental health

See the topic